Hucky Land Leads Genome Sequencing Project that Expands Tissue-Banking Partnership
Thursday, August 2, 2018
URMC recently extended a previous tissue-banking agreement with Indivumed, a private company, to include a new partnership for whole genome sequencing. Hucky Land, Ph.D., director of research at the Wilmot Cancer Institute, is leading the partnership with a project to sequence 2,000 colorectal cancer samples from 1,000 patients by the end of the year, and to develop novel software tools enabling complex cancer data analysis in the future.
The latest agreement with Indivumed also enabled the URMC Genomics Research Center (GRC) to purchase a state-of-the-art Illumina NovaSeq6000 DNA sequencer. The equipment signals a new era for genomics at the University, as it will aid research advancing personalized medicine, including discovery of new therapies to improve cancer outcomes. It also allows URMC investigators to perform whole genome sequencing for a fraction of the previous cost.
Based in Germany, Indivumed helped the URMC in 2016 set up a centralized tissue bank for collecting high-quality samples from surgical patients for cancer research. Once a tissue sample is examined to make a diagnosis, the remaining tissue is stored in the “Rochester Cancer Library” and available to URMC, Wilmot, and Indivumed scientists. The samples can be correlated with patient survival data, response to treatment, and other meaningful information for researchers.
In addition to Land, faculty who have been integral to the agreements with Indivumed include Steve Dewhurst, Ph.D., Vice Dean for Research at the SMD; David Linehan, M.D., chair of Surgery, director of Clinical Operations at Wilmot, and a pancreatic cancer researcher, who serves as the supervising investigator for tissue banking; and Bruce Smoller, M.D., chair of Pathology and Laboratory Medicine, who led efforts to operationalize the tissue bank.
Stephano Mello lab to open
Tuesday, July 10, 2018
Stephano is a currently a Postdoctoral fellow at Stanford University, and will join the faculty in the Department of Biomedical Genetics at the University of Rochester, in September 2018. Stephano is coming from Dr. Laura Attardi’s lab and his research seeks to understand the mechanisms behind pancreatic cancer initiation.
Please visit his lab site for more information.
Wilmot announces new Pilot Award recipients
Monday, April 30, 2018
Wilmot’s competitive seed-grant program aims to fund research projects that will generate preliminary data necessary to potentially apply for federal funding in the future. Thanks to financial support from two community organizations – Adding Candles for a Cure and the Edelman Gardner Cancer Research Foundation – four projects have received funding that started Jan. 1.
Mark Noble, Ph.D., Professor in the departments of Biomedical Genetics and Neuroscience, received a $50,000 grant for his project titled, “A biomarker for a novel glioblastoma (GBM) vulnerability.” The co-investigators for this project are Kevin Walter, M.D., Mahlon Johnson, M.D., Ph.D., Nimish Mohile, M.D., and Peggy Auinger, M.S.
Bradford Mahon, Ph.D., Assistant Professor in the Departments of Neurology and Neurosurgery, received a $50,000 grant for his project seeking to demonstrate feasibility and preliminary efficacy of advanced MRI mapping in improving outcome in patients with glioblastoma. Kevin Walter, M.D., is the co-investigator for this project.
Congratulations to all Wilmot pilot grant recipients.
Biological Sex Tweaks Nervous System Networks, Plays Role in Shaping Behavior
Thursday, March 8, 2018
By Mark Michaud
New research published today in the journal Current Biology demonstrates how biological sex can modify communication between nerve cells and generate different responses in males and females to the same stimulus. The findings could new shed light on the genetic underpinnings of sex differences in neural development, behavior, and susceptibility to diseases.
“While the nervous systems of males and females are virtually identical, we know that there is a sex bias in how many neurological diseases manifest themselves, that biological sex can influence behavior in animals, and that some of these differences are likely to be biologically driven,” said Douglas Portman, Ph.D., an associate professor in the Departments of Biomedical Genetics, Neuroscience, and the Center for Neurotherapeutics Discovery at the University of Rochester Medical Center (URMC) and lead author of the study. “This study demonstrates a connection between biological sex and the control and function of neural circuits and that these different sex-dependent configurations can modify behavior.”
The findings were made in experiments involving the nematode C. elegans, a microscopic roundworm that has long been used by researchers to understand fundamental mechanisms in biology. Many of the discoveries made using these worms apply throughout the animal kingdom and this research has led to a broader understanding of human biology. In fact, three Nobel Prizes in medicine and chemistry have been awarded for discoveries involving C. elegans.
The study focuses on the different behaviors of male and female worms. There are two sexes of C. elegans, males and hermaphrodites. Although the hermaphrodites are able to self-fertilize, they are also mating partners for males, and are considered to be modified females.
The behavior of C. elegans is driven by sensory cues, primarily smell and taste, which are used by the worms to navigate their environment and communicate with each other. Female worms secrete a pheromone that is known to attract males who are drawn by this signal in search of a mate. Other females, however, are repelled by the same pheromone. It is not entirely understood why, but scientists speculate that that the pheromone signals to females to avoid areas where there may be too much competition. Read More: Biological Sex Tweaks Nervous System Networks, Plays Role in Shaping Behavior
Leader in the field of epigenetic regulation and cancer biology joins the Department of Biomedical Genetics and GDSC Program
Wednesday, March 7, 2018
Dr. Paula Vertino, currently the leader of the Cancer Genetics and Epigenetics Program at Emory University will be joining the University of Rochester Department in Biomedical Genetics and the Wilmot Cancer Institute this summer. Dr. Vertino's research on cancer epigenetics will greatly expand our areas of research strengths. She is an exceptionally important player in her field, and we look forward to welcoming her to the GDSC program!Read More: Leader in the field of epigenetic regulation and cancer biology joins the Department of Biomedical Genetics and GDSC Program
Congratulations to our newly minted PhD’s!
Wednesday, February 28, 2018
Michelle Warren Millar
Through the course of her studies on melanoma, Michelle has found that GPR56 inhibits metastatic growth by preventing the expansion of micrometastases into macrometastases. Loss of GPR56 in highly metastatic cells promotes cell-ECM signaling in these metastatic lesions, and inhibition of this signaling results in smaller, less proliferative metastases, targeting one of the deadliest, metastasizing tumor types.
Yang’s research focuses on mechanisms that drive aging. Using Drosophila as a model, she showed that age-associated changes in chromatin structure explain why older organisms become more vulnerable to oxidative damage and decline functionally. Based on these findings she has developed strategies that can slow down epigenetic aging and improve the fitness of old organisms. This research raises intriguing implications for healthy aging in humans.
A Noble pursuit; finding the best science to help the most people
Tuesday, February 20, 2018
By Kevin McCormack
Mark Noble. Photo by Todd Dubnicoff
Mark Noble, Ph.D., is a pioneer in stem cell research and the Director of the University of Rochester Stem Cell and Regenerative Medicine Institute in New York. He is also a member of CIRM’s Grants Working Group (GWG), the panel of independent scientific experts we use to review research applications for funding and decide which are the most promising.
Mark has been a part of the GWG since 2011. When asked how he came to join the GWG he joked: “I saw an ad on Craigslist and thought it sounded fun.” But he is not joking when he says it is a labor of love.
“My view is that CIRM is one of the greatest experiments in how to develop a new branch of science and medicine. If you look at ventures, like the establishment of the National Institutes of Health, what you see is that when there is a concentrated effort to achieve an enormous goal, amazing things can happen. And if your goal is to create a new field of medicine you have to take a truly expansive view.”
Mark has been on many other review panels but says they don’t compare to CIRM’s.
“These are the most exciting review panels in which I take part. I don’t know of any comparable panels that bring together experts working across such a wide range of disciplines and diseases. It’s particularly interesting to be involved in reviews at this stage because we get to look at the fruits of CIRM’s long investment, and at projects that are now in, or well on the way towards, clinical trials.
It’s a wonderful scientific education because you come to these meetings and someone is submitting an application on diabetes and someone else has submitted an application on repairing the damage to the heart or spinal cord injury or they have a device that will allow you to transplant cells better. There are people in the room that are able to talk knowledgeably about each of these areas and understand how the proposed project might work in terms of actual financial development, and how it might work in the corporate sphere and how it fits in to unmet medical needs. I don’t know of any comparable review panels like this that have such a broad remit and bring together such a breadth of expertise. Every review panel you come to you are getting a scientific education on all these different areas, which is great.”
Another aspect of CIRM’s work that Mark admires is its ability to look past the financial aspects of research, to focus on the bigger goal:
“I like that CIRM recognizes the larger problem, that a therapy that is curative but costs a million dollars a patient is not going to be implemented worldwide. Well, CIRM is not here to make money. CIRM is here to find cures for unmet medical needs, which means that if someone comes in with a great application on a drug that is going to cure some awful disease and it’s not going to be worth a fortune, that is not the main concern. The main concern is that you might be able to cure this disease and yeah, we’ll put up money to help you so that you might be able to get into clinical trials, to get enough information to find out if it works. And to have the vision to go all the way from, ‘ok, you guys, we want you to enter this field, we want you to be interested in therapeutic development, we are going to help you structure the clinical trials, we are going to provide all the Alpha Stem Cell Clinics that can talk to each other to make the clinical trials happen.
The goal of CIRM is to change medicine and these are the approaches that have worked really well in doing this. The CIRM view clearly is:
‘There are 100 horses in this race and every single one that crosses the finish line is a success story.’ That’s what is necessary, because there are so many diseases and injuries for which new approaches are needed.”
Mark says working with CIRM has helped him spread the word back home in New York state:
“I have been very involved in working with the New York state legislature over the years to promote funding for stem cell biology and spinal cord injury research so having the CIRM experience has really helped me to understand what it is that another place can try and accomplish. A lot of the ideas that have been worked out at CIRM have been extremely helpful for statewide scientific enterprises in New York, where we have had people involved in different areas of the state effort talk to people at CIRM to find out what best practice is.”
Mark says he feels as if he has a front row seat to history.
Read More: A Noble pursuit; finding the best science to help the most people
“Seeing the stem cell field grow to its present stage and enhancing the opportunity to address multiple unmet medical needs, is a thrilling adventure. Working with CIRM to help create a better future is a privilege.”